Endoscopic submucosal dissection for premalignant lesions and noninvasive early gastrointestinal cancers

Hülagü, Sadettin; Şentürk, Ömer; Aygün, Cem; Kocaman, Orhan; Çelebi, Altay; Konduk, Tolga; Koç, Deniz Öğütmen; Şirin, Göktuğ; Korkmaz, Uğur; Duman, Ali; Bozkurt, Neslihan; Dindar, Gökhan; Attila, Tan; Gürbüz, Yeşim; Tarçın, Özlem; Kalaycı, Cem

doi:10.3748/wjg.v17.i13.1701

Cited by 23 publications

(11 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, Sakamoto et al [22] and Ohata et al [23] showed that 30 ESD treatments performed independently in the colon were sufficient to obtain an acceptable R0 resection rate, procedure duration, and complication rate. This learning curve was confirmed by studies showing that during the first 25 treatments, the perforation rates were 12-28% [24][25][26][27]. In a European study, Probst et al [15] observed a considerable improvement in resection parameters after two endoscopists each performed 25 procedures as the procedure time decreased from about 200 to 136 min and the proportion of R0 resections increased from 48 to 84.5%.…”

Section: Discussionmentioning

confidence: 87%

Treatment of large colorectal neoplasms by endoscopic submucosal dissection

Białek

Pertkiewicz²,

Karpińska-Kaczmarczyk³

et al. 2014

European Journal of Gastroenterology &Amp; Hepatology

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 87%

Treatment of large colorectal neoplasms by endoscopic submucosal dissection

Białek

Pertkiewicz²,

Karpińska-Kaczmarczyk³

et al. 2014

European Journal of Gastroenterology &Amp; Hepatology

View full text Add to dashboard Cite

show abstract

“…In Turkey, the early gastric cancer ratio is lower than 10% among all gastric cancer cases and exhibits a parallel trend to other European countries (7,8). Although there are centers in Turkey that successfully perform endoscopic resections for cancer, it is challenging to increase the case volume due to the lack of a screening program for gastric cancer.…”

Section: Management Of Locoregional Diseasementioning

confidence: 99%

Recent trends of gastric cancer treatment in Turkey

Güner

2017

Transl. Gastroenterol. Hepatol.

View full text Add to dashboard Cite

Gastric cancer is the fifth most common type of cancer and is the fourth most common death due to cancer in Turkey. Incidence and mortality rates are one of the highest among European countries. Despite the high rates, management of gastric cancer is still an issue of debate in Turkey and national guidelines have yet to be established. While the treatment plan following the diagnosis of gastric cancer is determined by a multidisciplinary meeting at high-volume centers, the plan in the majority of cases in Turkey is decided based on the decision of an individual physician. The primary goal of the treatment strategy is to obtain the best oncological outcomes and quality of life within the acceptable treatment-related morbidity. Therefore, R0 resection is intended by using standardized surgery with an individualized approach, while avoiding surgery if a curative resection is not possible. In this review, presenting on the recent trends of gastric cancer treatment including surgical, endoscopic, adjuvant/neoadjuvant and conversion treatment options in Turkey are aimed by exploring the institutional approach.

show abstract

“…Endoscopic Submucosal Dissection (ESD) has been shown to be safe for larger lesions and those not amenable to EMR, with high en bloc complete resection rates in experienced centres mostly in Japan. [61][62][63][64] However, it is not widely available in the UK and the majority of evidence for ESD for NETs is from the rectal carcinoid literature. [65][66][67][68][69] Endoscopic resection of nonmetastatic localised lesions <2 cm with ≤6 lesions has been demonstrated to be as effective as surgical resection.…”

Section: Treatment and Surveillancementioning

confidence: 99%

Review article: the investigation and management of gastric neuroendocrine tumours

Basuroy

Haji

Ramage

et al. 2014

Aliment Pharmacol Ther

127

View full text Add to dashboard Cite

Summary Background Gastric carcinoids (GCs) or neuroendocrine tumours (NETs) are increasingly identified at endoscopy, and account for 0.6–2% of all gastric polyps identified. The SEER database in the US has demonstrated a rising incidence of gastric NETs amongst all NETs; from 2.2% between 1950 and 1969 to 6.0% between 2000 and 2007. Aim To review the literature and assist clinicians in managing patients with GCs. Methods A literature search was conducted through MEDLINE using search terms: gastric, carcinoid, neuroendocrine tumour, therapy, endoscopy, mucosal resection, submucosal dissection. Relevant articles were identified through manual review. The reference lists of these articles were reviewed to include further appropriate articles. Results There are three types of GCs with important epidemiological, pathophysiological, histological and endoscopic differences that affect prognosis and management. Type 1 and 2 GCs develop in the context of hypergastrinaemia that originates from achlorhydria in atrophic gastritis and a gastrinoma, respectively. Type 3 GCs occur sporadically and independent of gastrin. The histological type, grade and Ki67 index are used to determine prognosis and direct clinical management. Type 1 GCs >1 cm in size and type 2 GCs should be assessed for invasion beyond the submucosa with EUS prior to endoscopic resection with EMR or ESD. Type 3 GCs should be managed as per recommendations for gastric adenocarcinoma. The treatment of advanced disease is multimodal. Conclusions Patients with gastric carcinoids should be discussed in a specialist neuroendocrine tumour multidisciplinary meeting to ensure all treatment options are explored in localised and advanced disease. Areas of controversy exist that need further research.

show abstract

Endoscopic submucosal dissection for premalignant lesions and noninvasive early gastrointestinal cancers

Abstract: ESD is a feasible and safe method for treatment of premalignant lesions and early malignant gastrointestinal epithelial and subepithelial lesions. Successful en bloc and complete resection of lesions yield high cure rates with low recurrence.

Cited by 23 publications

References 15 publications

Treatment of large colorectal neoplasms by endoscopic submucosal dissection

Treatment of large colorectal neoplasms by endoscopic submucosal dissection

Recent trends of gastric cancer treatment in Turkey

Review article: the investigation and management of gastric neuroendocrine tumours

Contact Info

Product

Resources

About